Pfizer Inc. (PFE)
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer's Comeback Is Underway
Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines, and internal medicine, plus a robust R&D pipeline. Major patent expirations threaten $15B+ in annual revenue by 2028, but Pfizer is aggressively pursuing pipeline and acquisition strategies.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatment response in bladder cancer patients. The findings, from the JAVELIN Bladder 100 Trial involving 496 patients, were featured in the journal Cancers.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
